Discovery of potent and brain-penetrable tubulin inhibitors that effectively suppress breast cancer brain metastasis.

ABSTRACT: Breast cancer brain metastasis (BCBM) remains a clinical challenge marked by limited therapeutic options and poor survival rates. Approximately 30% of all metastatic breast cancer patients develop BCBM, with the highest incidence in patients with aggressive molecular subtypes, including triple-negative breast cancer (TNBC). TNBC patients with brain metastasis experience rapid disease progression and significantly reduced survival times due to a lack of targeted treatments that can penetrate the blood-brain barrier (BBB) and effectively control metastatic expansion. Current treatment options, such as whole-brain radiotherapy and chemotherapy, offer limited efficacy and are associated with significant toxicities, underscoring the urgent need for novel therapeutics that can target BCBM direct

SUBMITTER: Krutilina RI 

PROVIDER: S-EPMC12830028 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature